First patient has been enrolled
in the phase III study CONCLUDE
with cobitolimod in ulcerative colitis
Interview with CEO Peter Zerhouni about the enrollment of the first patient in the phase III study CONCLUDE and the way forward.
InDex Pharmaceuticals would like to raise the awareness of World IBD Day by wearing the Purple Ribbon, an international symbol of inflammatory bowel disease (IBD).
Our mission is to significantly improve
the lives of patients suffering from
immunological disorders by providing
effective and safe drugs for diseases
with high unmet medical needs.
-
InDex Pharmaceuticals enrols first patient in the PK study with cobitolimod
December 8, 2021 Non Regulatory
-
InDex Pharmaceuticals enrols first patient in the phase III study CONCLUDE with cobitolimod in ulcerative colitis
November 24, 2021 Regulatory
InDex Pharmaceuticals Holding AB (publ) published its interim report Q3 for January-September 2021 on November 24, 2021 at 08:00 a.m. CET.
-
Deep dive presentation of the design of the phase III study CONCLUDE at HC Andersen Capital’s online event
-
Year-end Report 2021
-
Annual Report 2021
Our phase III study CONCLUDE
Have a look at InDex’s corporate presentation
InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis
Proud partner of:
